The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

Results from a case series identified a potential association between ophthalmic complications and the rapid correction of hyperglycemia, brought on by patients using either semaglutide or tirzepatide ...

Kidney disease treatment is undergoing a transformation, driven by exciting new research that reveals the protective power of semaglutide in patients with type 2 diabetes. Semaglutide, a ...

Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

The drugs became so popular so fast that manufacturers began running out, and patients scrambled to find Ozempic or Wegovy (the brand-name versions of semaglutide) and Monjauro or Zepbound ...

The type 2 diabetes medication, generically known as semaglutide, has received unprecedented ... in East Asian patients, type 2 diabetes develops at lower BMI, and fat accumulation tends to ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient ... depending on the patient's response. In clinical trials, Victoza helped lower A1C by up to 1.5%.